CA2560012A1 - A method for chromatographic purification - Google Patents
A method for chromatographic purification Download PDFInfo
- Publication number
- CA2560012A1 CA2560012A1 CA002560012A CA2560012A CA2560012A1 CA 2560012 A1 CA2560012 A1 CA 2560012A1 CA 002560012 A CA002560012 A CA 002560012A CA 2560012 A CA2560012 A CA 2560012A CA 2560012 A1 CA2560012 A1 CA 2560012A1
- Authority
- CA
- Canada
- Prior art keywords
- ion
- matrix
- peg
- exchange chromatography
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- 238000011097 chromatography purification Methods 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 94
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 53
- 229920000570 polyether Polymers 0.000 claims abstract description 49
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 45
- 239000012504 chromatography matrix Substances 0.000 claims abstract description 31
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 238000011210 chromatographic step Methods 0.000 claims abstract description 23
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 22
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 19
- -1 poly(ethylene glycol) Polymers 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 239000003446 ligand Substances 0.000 claims description 41
- 239000011159 matrix material Substances 0.000 claims description 36
- 239000000872 buffer Substances 0.000 claims description 35
- 239000004606 Fillers/Extenders Substances 0.000 claims description 33
- 238000004587 chromatography analysis Methods 0.000 claims description 32
- 238000001179 sorption measurement Methods 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 24
- 238000009739 binding Methods 0.000 claims description 24
- 230000003993 interaction Effects 0.000 claims description 17
- 239000000969 carrier Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 229920002307 Dextran Polymers 0.000 claims description 13
- 238000005342 ion exchange Methods 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 2
- 239000000306 component Substances 0.000 claims 3
- 238000011091 antibody purification Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 67
- 239000012071 phase Substances 0.000 description 40
- 150000003839 salts Chemical class 0.000 description 30
- 230000008569 process Effects 0.000 description 22
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 229940098773 bovine serum albumin Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 17
- 238000000746 purification Methods 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000010828 elution Methods 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 9
- 229920000936 Agarose Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 238000001742 protein purification Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 235000010633 broth Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102100032241 Lactotransferrin Human genes 0.000 description 4
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
- 235000021242 lactoferrin Nutrition 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 230000002535 lyotropic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000337 buffer salt Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 2
- 108091006522 Anion exchangers Proteins 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000012516 mab select resin Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- QSISWYUKPMXKSO-UHFFFAOYSA-N 2-(2-phenylethenoxymethyl)oxirane Chemical compound C1OC1COC=CC1=CC=CC=C1 QSISWYUKPMXKSO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000007825 activation reagent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 229940117927 ethylene oxide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000000506 liquid--solid chromatography Methods 0.000 description 1
- 230000010874 maintenance of protein location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/38—Flow patterns
- G01N30/46—Flow patterns using more than one column
- G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400886A SE0400886D0 (sv) | 2004-04-02 | 2004-04-02 | Process of purification |
| SE0400886-8 | 2004-04-02 | ||
| PCT/SE2005/000467 WO2005094960A1 (en) | 2004-04-02 | 2005-03-31 | A method for chromatographic purification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2560012A1 true CA2560012A1 (en) | 2005-10-13 |
Family
ID=32173667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002560012A Abandoned CA2560012A1 (en) | 2004-04-02 | 2005-03-31 | A method for chromatographic purification |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070213513A1 (enExample) |
| EP (1) | EP1729867B1 (enExample) |
| JP (1) | JP4831697B2 (enExample) |
| AT (1) | ATE485880T1 (enExample) |
| AU (1) | AU2005228834A1 (enExample) |
| CA (1) | CA2560012A1 (enExample) |
| DE (1) | DE602005024373D1 (enExample) |
| SE (1) | SE0400886D0 (enExample) |
| WO (1) | WO2005094960A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842964A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| US8268915B2 (en) * | 2007-06-19 | 2012-09-18 | Ge Healthcare Bio-Sciences Ab | Polymer two phase system and use thereof |
| WO2009090056A2 (en) | 2008-01-18 | 2009-07-23 | F. Hoffmann-La Roche Ag | Purification of not-glycosylated polypeptides |
| US8372286B2 (en) * | 2008-02-05 | 2013-02-12 | Ge Healthcare Bio-Sciences Ab | Method for production of separation media |
| FR2930780B1 (fr) * | 2008-04-30 | 2010-08-20 | Moet & Chandon | Procede de degorgement de vins mousseux |
| JP2011522055A (ja) * | 2008-06-03 | 2011-07-28 | パトリス リミテッド | 抗体の精製のためのプロセス |
| AU2009307737B2 (en) | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
| NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| EP2686334B2 (en) | 2011-03-16 | 2020-07-01 | F.Hoffmann-La Roche Ag | Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase |
| US9624261B2 (en) | 2011-03-29 | 2017-04-18 | Glaxosmithkline Llc | Buffer system for protein purification |
| CN103717284B (zh) * | 2011-06-08 | 2016-02-24 | 新加坡科技研究局 | 通过约束共水合色谱纯化生物制品 |
| EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| CN105555795A (zh) * | 2013-09-17 | 2016-05-04 | 株式会社钟化 | 新抗体纯化方法和由该方法得到的抗体、以及使用了阳离子交换基团的新抗体纯化法和由该方法得到的抗体 |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| SG11201900201YA (en) | 2016-08-16 | 2019-02-27 | Regeneron Pharma | Methods for quantitating individual antibodies from a mixture |
| AU2017350807B2 (en) | 2016-10-25 | 2022-07-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
| CN118416215A (zh) | 2017-09-19 | 2024-08-02 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| CN108152104B (zh) * | 2017-12-25 | 2020-08-11 | 上海微谱化工技术服务有限公司 | 超支化水性聚氨酯中二氧化硅填料的分离及定量方法 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| US11420916B2 (en) * | 2018-06-08 | 2022-08-23 | Board Of Regents, The University Of Texas System | Systems and methods for separation of olefins from mixtures that contain reducing agents |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| KR20220078634A (ko) * | 2019-10-04 | 2022-06-10 | 메르크 파텐트 게엠베하 | 단백질 a 친화성 크로마토그래피에서 모노클로날 항체의 용리 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| DE3483620D1 (de) * | 1983-03-11 | 1991-01-03 | Fujirebio Kk | Verfahren zur bestimmung von liganden. |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| DE3789413T2 (de) * | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
| US5151358A (en) * | 1989-06-13 | 1992-09-29 | Genencor International, Inc. | Processes for the recovery of naturally produced chymosin |
| DE4321904B4 (de) * | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US5561064A (en) * | 1994-02-01 | 1996-10-01 | Vical Incorporated | Production of pharmaceutical-grade plasmid DNA |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| SE9503925D0 (sv) * | 1995-11-07 | 1995-11-07 | Pharmacia Biotech Ab | Separationsmedium för IgG |
| US20020006405A1 (en) * | 1996-10-22 | 2002-01-17 | Masaki Kitajima | Sepsis remedy comprising anti-il-8 antibody as active ingredient |
| AUPR110100A0 (en) * | 2000-10-30 | 2000-11-23 | Life Therapeutics Limited | Improved separation of macromolecules |
| US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US7998705B2 (en) * | 2002-08-06 | 2011-08-16 | FUJIFILM Diosynth Biotechnologies U.S.A., Inc | Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol |
| US20060275766A1 (en) * | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
-
2004
- 2004-04-02 SE SE0400886A patent/SE0400886D0/xx unknown
-
2005
- 2005-03-31 WO PCT/SE2005/000467 patent/WO2005094960A1/en not_active Ceased
- 2005-03-31 CA CA002560012A patent/CA2560012A1/en not_active Abandoned
- 2005-03-31 AT AT05722292T patent/ATE485880T1/de not_active IP Right Cessation
- 2005-03-31 JP JP2007506111A patent/JP4831697B2/ja not_active Expired - Lifetime
- 2005-03-31 AU AU2005228834A patent/AU2005228834A1/en not_active Abandoned
- 2005-03-31 EP EP05722292A patent/EP1729867B1/en not_active Expired - Lifetime
- 2005-03-31 DE DE602005024373T patent/DE602005024373D1/de not_active Expired - Lifetime
- 2005-03-31 US US10/594,187 patent/US20070213513A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1729867A1 (en) | 2006-12-13 |
| SE0400886D0 (sv) | 2004-04-02 |
| DE602005024373D1 (de) | 2010-12-09 |
| EP1729867B1 (en) | 2010-10-27 |
| ATE485880T1 (de) | 2010-11-15 |
| WO2005094960A1 (en) | 2005-10-13 |
| JP4831697B2 (ja) | 2011-12-07 |
| AU2005228834A1 (en) | 2005-10-13 |
| US20070213513A1 (en) | 2007-09-13 |
| JP2007530971A (ja) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1729867B1 (en) | A method for chromatographic purification | |
| Hjerten et al. | Gels mimicking antibodies in their selective recognition of proteins | |
| JP4776615B2 (ja) | 抗体精製 | |
| Jungbauer et al. | Ion-exchange chromatography | |
| JP5148484B2 (ja) | クロマトグラフィーマトリックスの再生 | |
| JPH11506603A (ja) | 新規因子ｉｘ精製法 | |
| EP1963367A2 (en) | Polishing steps used in multi-step protein purification processes | |
| Chicz et al. | [32] High-performance liquid chromatography: Effective protein purification by various chromatographic modes | |
| WO2006011839A1 (en) | Chromatography method | |
| El Rassi et al. | Reversed-phase and hydrophobic interaction chromatography of peptides and proteins | |
| EP2488295A1 (en) | Separation matrices | |
| Hedhammar et al. | Chromatographic methods for protein purification | |
| Jeno et al. | Desalting electroeluted proteins with hydrophilic interaction chromatography | |
| Janson et al. | Introduction to chromatography | |
| Choudhary et al. | [3] Ion-exchange chromatography | |
| Lu et al. | Evaluation on adsorption selectivity of immunoglobulin G with 2-mercapto-1-methyl-imidazole-based hydrophobic charge-induction resins | |
| EP2012118A1 (en) | SEPARATING AGENT FOR IgG PURIFICATION, AND METHOD FOR PURIFYING AN IgG MONOMER USING IT | |
| Turková | Bioaffinity chromatography | |
| Porath et al. | Thiophilic adsorption: A new kind of molecular interaction revealed by chromatography | |
| EP1455920B1 (en) | Separation method | |
| Hammond et al. | High-resolution fractionation of proteins in downstream processing | |
| WO1991014706A2 (en) | Lectin affinity membranes and methods for using them | |
| Varilova et al. | Separation media in affinity chromatography of proteins-A critical review | |
| Li et al. | High-performance liquid chromatography of proteins on deformed nonporous agarose beads: immuno-affinity chromatography, exemplified with human growth hormone as ligand and a combination of ethylene glycol and salt for desorption of the antibodies | |
| CN118922247A (zh) | 碱稳定的κ轻链结合分离基质 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |